Polycystic ovary syndrome (PCOS, recently renamed polyendocrine metabolic ovarian syndrome or PMOS) is driven at its core by selective insulin resistance. Gold-standard insulin-clamp cohorts (Stepto et al.; Tosi et al.) confirm that 59% to 75% of lean women and 94% to 95% of overweight women with PCOS are insulin resistant: their skeletal muscle resists insulin's glucose uptake, while their ovarian theca cells stay sensitive to insulin and pump out 3 to 4 times more testosterone as liver SHBG drops. Under the 2023 International Guideline, adult diagnosis requires 2 of 3 features (irregular ovulation, clinical or lab androgen excess, and either >=20 follicles per ovary on ultrasound or a high serum AMH). For fertility, letrozole is first-line over clomiphene (27.5% vs. 19.1% live birth in PPCOS II); for metabolism and cycles, nutrition, strength training, metformin, GLP-1 agonists, and optional 40:1 myo-/D-chiro-inositol target the root driver.
TL;DR: Insulin-clamp studies prove that 59% to 75% of lean women and 94% to 95% of overweight women with PCOS have insulin resistance. Muscle cells resist insulin's blood-sugar signal, forcing the pancreas to pump out extra insulin. That high insulin tells ovarian cells to make 3 to 4 times more testosterone while shutting down liver SHBG production. Under the 2023 Guideline, adult diagnosis requires 2 of 3 features: irregular ovulation, high androgens, and either >= 20 follicles per ovary on ultrasound or a high AMH blood test (neither test is used within 8 years of a first period). Because HbA1c and fasting glucose miss nearly half of PCOS blood-sugar problems, a 2-hour 75 g oral glucose test (OGTT) is the gold standard. For pregnancy, letrozole beats clomiphene (27.5% vs. 19.1% live birth). Metformin, GLP-1 medications, strength training, and spironolactone plus contraception each serve specific metabolic, cycle, and skin goals.
When a 29-year-old graphic designer from Fishtown came in after stopping her birth control pill eight months earlier, she had gone 140 days without a period and was breaking out along her jawline. She was lifting at City Fitness three days a week and had a "normal" HbA1c of 5.3%. Her prior clinic had told her that her normal HbA1c and BMI of 22 ruled out metabolic PCOS. Yet her fasting insulin came back at 16 µIU/mL, her SHBG was 21 nmol/L, her AMH was 8.4 ng/mL, and her 2-hour oral glucose test hit 162 mg/dL. Once we treated that hidden muscle insulin resistance with metformin, strength training, and a protein-anchored breakfast, her natural 31-day ovulatory cycle returned in 11 weeks.
How do you diagnose PCOS under the 2023 International Guideline (and where does AMH fit)?
Under the 2023 International Guideline (Teede et al., backed by 39 groups across 195 countries), diagnosing PCOS in an adult woman requires at least 2 of 3 criteria.12 First, a doctor must rule out hormone mimics (TSH for thyroid disease, prolactin, and morning 17-hydroxyprogesterone for adrenal conditions):1
- Irregular ovulation: Cycles shorter than 21 days or longer than 35 days (or fewer than 8 periods per year) in adults more than 3 years past their first period.1
- Clinical or lab androgen excess: Unwanted dark facial, chest, or belly hair (hirsutism), jawline acne, or scalp hair thinning, or high blood androgens.1 We measure blood androgens using LC-MS/MS total testosterone and free testosterone via SHBG (plus DHEA-S and androstenedione when needed).1
- Polycystic ovaries on ultrasound OR high serum AMH (step 3 only): If a woman already has both irregular cycles and high androgens (Criteria 1 + 2), the diagnosis is complete. Neither an ultrasound nor an AMH test is needed.12 When only one of those two features is present in an adult, the 2023 guideline allows either a transvaginal ultrasound (>= 20 follicles per ovary or ovarian volume >= 10 mL) or a high AMH blood test to count as the third feature.13
Three simple rules prevent misdiagnosis:134
- Pick either ultrasound OR AMH (do not order both): Across 68 adult studies (van der Ham et al., 2024), blood AMH spots PCOS with 79% sensitivity and 87% specificity.3 Ultrasound follicle count shows 84% sensitivity and 91% specificity.3 Ordering both tests causes false positives, and AMH must never be used alone without irregular cycles or high androgens.1
- Account for birth control, BMI, and lab platform: Birth control pills lower AMH by 24% to 25% (Hariton et al., n = 27,125), and higher BMI also lowers AMH.13 Lab platforms report different numbers (~5.7 ng/mL cutoff in women in their 20s vs. ~3.7 ng/mL at ages 35 to 40).13
- Never use ultrasound or AMH within 8 years of a first period (teenagers): Up to 40% of healthy teenagers have many small follicles on ultrasound two years after their first period.4 AMH also peaks at ages 20 to 25, dropping its accuracy to 66% in teens.14 Teenagers need both high androgens and irregular cycles for a diagnosis. Teens with only one feature are followed as "at risk" and re-checked 8 years after their first period.4 (In May 2026, a global panel also began shifting the name from PCOS to polyendocrine metabolic ovarian syndrome, or PMOS because ovarian "cysts" are paused egg follicles.)
Why do lean women get insulin-resistant PCOS, and how does insulin drive high testosterone?
A common myth is that insulin resistance only affects women with higher body weight. When researchers measure sugar uptake directly using the gold-standard insulin clamp, insulin resistance shows up in most lean women with PCOS and nearly all overweight women:56
- Stepto et al. (Human Reproduction 2013, clamp study): 75% of lean women with PCOS and 95% of overweight women with PCOS were insulin resistant.5
- Tosi et al. (Human Reproduction 2017, n = 375 clamp cohort): 59.3% of normal-weight women, 77.5% of overweight women, and 93.9% of women with obesity had clamp-proven insulin resistance (74.9% overall).6
- Cassar et al. (28 clamp studies): Women with PCOS carry a 27% drop in insulin sensitivity at any weight, and excess weight adds a further 15% drop.6
How can a woman's muscles resist insulin while her ovaries over-respond to it? Andrea Dunaif's studies solved this puzzle by showing that PCOS involves selective post-receptor insulin resistance.7 Inside muscle and fat cells, serine phosphorylation (Ser312) on IRS-1 blocks the PI3K-Akt-GLUT4 pathway that pulls sugar out of the blood.7 Because muscle cannot clear sugar well, the pancreas pumps out extra insulin.
Meanwhile, the ovary and liver stay sensitive to that high insulin flood, causing a double hit on testosterone:278
- Ovarian theca cells pump out 3 to 4 times more androgens: Insulin acts as a partner hormone alongside LH. Working through ovarian PI3-kinase, insulin plus LH boosts CYP17A1 and StAR gene activity 3.4- to 4.1-fold.7 That drives a 3- to 4-fold surge in androstenedione and testosterone.7 High insulin also lowers liver IGFBP-1, which raises free IGF-1 to stimulate theca cells further.2
- Liver SHBG drops, sending free testosterone soaring: In the liver, high insulin and sugar-driven fat synthesis turn down HNF-4α at the SHBG gene.8 SHBG is the protein sponge that binds testosterone in the blood. When SHBG drops, a much larger share of testosterone stays free and active to cause jawline acne, facial hair, scalp hair thinning, and stalled ovulation.8
Why does HbA1c miss half of PCOS blood-sugar problems?
PCOS insulin resistance begins in muscle (which clears 70% to 80% of a meal's sugar load) instead of the fasting liver. Women with PCOS therefore develop high after-meal blood sugar years before their fasting glucose or HbA1c moves:19
- In Celik et al. (n = 252), an HbA1c >= 5.6% had only 52.4% sensitivity. It missed nearly half (20 of 41) of women who failed an oral glucose test.9
- In Lerchbaum et al. (n = 671), HbA1c >= 5.7% caught only 3.2% of women as prediabetic compared with 12.8% caught by full oral glucose testing (κ = 0.36). In Ortiz-Flores et al., fasting glucose alone missed ~40% of cases.9
The 2023 Guideline therefore recommends screening every woman with PCOS at diagnosis using a 2-hour 75 g oral glucose test (OGTT) at any BMI. Repeat it every 1 to 3 years, before trying to conceive, and in pregnancy.1 HbA1c and fasting glucose are far less accurate on their own.1 In our clinic, we pair glucose testing with fasting insulin (optimal < 6 µIU/mL), SHBG, apoB, triglycerides, and ALT to track progress over 12-week blocks.
How do letrozole, metformin, inositol, spironolactone, and GLP-1s compare in randomized trials?
Every medication or supplement in PCOS has a specific job. Choosing the right one depends on whether your main goal today is getting pregnant, reversing insulin resistance and restoring natural cycles, or clearing androgen-driven acne and facial hair:11011
| Treatment | Landmark Trial Evidence | What It Does Best | 2023 Guideline Role & Key Nuance |
|---|---|---|---|
| Letrozole (2.5 to 7.5 mg days 3 to 5) | PPCOS II (NEJM 2014; n = 750) & Cochrane (41 RCTs) | Live birth 27.5% vs. 19.1% on clomiphene (RR 1.44, Cochrane OR 1.72, NNT ~10); ovulation 61.7% vs. 48.3%; twins 3.4% vs. 7.4%.10 | First-line ovulation induction across all BMI groups (HR 1.72 faster time to pregnancy).110 |
| Metformin (1,500 to 2,000 mg/day ER) | PPCOS I (NEJM 2007; n = 626) & IPD meta-analysis | Lowers insulin, weight, and metabolic risk; restores ovulation, though live birth alone is 7.2% vs. 22.5% for clomiphene.11 | First-line metabolic agent (preferred over birth control for insulin and weight); used as an add-on instead of a solo fertility drug.111 |
| Myo- / D-Chiro-Inositol (4 g/day, 40:1) | Fitz et al. (30 RCTs, JCEM 2024); Pundir MA; Nordio (n = 56) | Restores ovulation (RR 2.3 vs. placebo) and lowers insulin with minimal GI upset; metformin beat inositol for waist-hip ratio and hirsutism.12 | "Could be considered" based on patient preference; guideline declines to endorse a specific dose or 40:1 ratio due to small trials and lack of live-birth endpoints.112 |
| Combined Oral Contraceptive (COC) + Spironolactone (25 to 100 mg/day) | Barrionuevo network MA (43 RCTs); Alpañés 1-yr RCT | Strongest drop in hirsutism (-4.6 points better on Ferriman-Gallwey hair score than metformin) and jawline acne.13 | COC first-line for cycles/androgens; add spironolactone if hair/acne response is incomplete after >= 6 months. Strict contraception required (male fetus risk).113 |
| GLP-1 Agonists (semaglutide, tirzepatide, liraglutide) | Elkind-Hirsch Phase 3 (liraglutide 3 mg, 32 wks); Kar et al. 2026 MA | Weight -5.7% vs. -1.4%, BMI -2.42, waist -5.16 cm, lower free androgen index; natural pregnancy OR 3.10 vs. metformin (4 RCTs).14 | High-impact tool for metabolic/obesity-driven PCOS; must stop with washout before conception (contraception required while on drug).114 |
Guidance from the Clinic
Key Takeaways
- 2023 diagnostic rule: Adult PCOS requires 2 of 3 features - irregular ovulation, high androgens, and either >= 20 follicles per ovary on ultrasound or a high AMH blood test.13 Do not order both ultrasound and AMH, do not use AMH alone, and do not use either test within 8 years of a first period.14
- Insulin resistance hits lean women too: Clamp studies confirm insulin resistance in 59% to 75% of lean women and 94% to 95% of overweight women with PCOS (Stepto et al., Tosi et al.). That boosts ovarian androgen output 3- to 4-fold while lowering liver SHBG.5678
- Do not rely on HbA1c alone: Because PCOS blood-sugar issues start in muscle after meals, HbA1c and fasting glucose miss 40% to 48% of cases. The 2-hour 75 g oral glucose test (OGTT) is the recommended screen across all BMI groups.19
- Match treatment to your primary goal: Letrozole is first-line for ovulation and live birth (27.5% vs. 19.1% for clomiphene in PPCOS II). Metformin and GLP-1 medications (with preconception washout) lead for metabolic and weight repair. Birth control plus spironolactone leads for unwanted hair and acne, and inositol is a gentle add-on.110121314
Related at Fishtown Medicine
- PCOS Is Now PMOS: Why the Name Changed and How to Get Diagnosed - the 2026 Lancet rename to Polyendocrine Metabolic Ovarian Syndrome and our full first-visit lab panel
- AMH and Ovarian Reserve Testing - how AMH works in PCOS diagnosis, IVF planning, and egg freezing
- Inositol: A Clinical Guide - how myo- and D-chiro-inositol work and where the 2023 guideline draws the line
- Fertility Optimization - our 90-day preconception metabolic and hormone runway
- Hormone Testing Before Birth Control - why combined oral contraceptives lower AMH by 25% and mask androgen labs
- Hidradenitis Suppurativa - the inflammatory skin condition that travels with PCOS and insulin resistance
- The Hair Playbook - treating androgen-driven scalp thinning and unwanted facial hair
Scientific References
- Teede HJ, Tay CT, Laven JJE, et al. "Recommendations From the 2023 International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome." Journal of Clinical Endocrinology & Metabolism. 2023;108(10):2447-2469.
- Stener-Victorin E, Teede H, Norman RJ, et al. "Polycystic ovary syndrome." Nature Reviews Disease Primers. 2024;10:27.
- van der Ham K, Laven JSE, Tay CT, et al. "Anti-Müllerian Hormone as a Diagnostic Biomarker for Polycystic Ovary Syndrome and Polycystic Ovarian Morphology: A Systematic Review and Meta-Analysis." Fertility and Sterility. 2024;122(4):727-739. And Hariton E, Shirazi TN, Douglas NC, Hershlag A, Briggs SF. "Anti-Müllerian Hormone Levels Among Contraceptive Users: Evidence From a Cross-Sectional Cohort of 27,125 Individuals." American Journal of Obstetrics and Gynecology. 2021;225(5):515.e1-515.e10.
- Peña AS, Witchel SF, Boivin J, et al. "International evidence-based recommendations for polycystic ovary syndrome in adolescents." BMC Medicine. 2025;23:112.
- Stepto NK, Cassar S, Joham AE, et al. "Women With Polycystic Ovary Syndrome Have Intrinsic Insulin Resistance on Euglycaemic-Hyperinsulaemic Clamp." Human Reproduction. 2013;28(3):777-784.
- Tosi F, Bonora E, Moghetti P. "Insulin Resistance in a Large Cohort of Women With Polycystic Ovary Syndrome: A Comparison Between Euglycaemic-Hyperinsulinaemic Clamp and Surrogate Indexes." Human Reproduction. 2017;32(12):2515-2521. And Cassar S, Misso ML, Hopkins WG, et al. Human Reproduction. 2016;31(11):2619-2631.
- Dunaif A. "Insulin Resistance and the Polycystic Ovary Syndrome: Mechanism and Implications for Pathogenesis." Endocrine Reviews. 1997;18(6):774-800; Corbould A, Kim YB, Youngren JF, et al. American Journal of Physiology - Endocrinology and Metabolism. 2005;288(5):E1047-E1054. And Zhang G, Garmey JC, Veldhuis JD. Endocrinology. 2000;141(8):2735-2742.
- Selva DM, Hogeveen KN, Innis SM, Hammond GL. "Monosaccharide-Induced Lipogenesis Regulates the Human Hepatic Sex Hormone-Binding Globulin Gene." Journal of Clinical Investigation. 2007;117(12):3979-3987.
- Celik C, Abali R, Bastu E, et al. "Assessment of Impaired Glucose Tolerance Prevalence With Hemoglobin A1c and Oral Glucose Tolerance Test in 252 Turkish Women With Polycystic Ovary Syndrome." Human Reproduction. 2013;28(4):1062-1068. And Lerchbaum E, Schwetz V, Giuliani A, Obermayer-Pietsch B. Human Reproduction. 2013;28(9):2485-2494.
- Legro RS, Brzyski RG, Diamond MP, et al. "Letrozole versus Clomiphene for Infertility in the Polycystic Ovary Syndrome (PPCOS II)." New England Journal of Medicine. 2014;371(2):119-129. And Franik S, Le QK, Kremer JAM, et al. Cochrane Database of Systematic Reviews. 2022;(9):CD010287.
- Legro RS, Barnhart HX, Schlaff WD, et al. "Clomiphene, Metformin, or Both for Infertility in the Polycystic Ovary Syndrome (PPCOS I)." New England Journal of Medicine. 2007;356(6):551-566. And Wang R, Li W, Bordewijk EM, et al. Human Reproduction Update. 2019;25(6):691-707.
- Fitz V, Graca S, Mahalingaiah S, et al. "Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines." Journal of Clinical Endocrinology & Metabolism. 2024;109(6):1630-1655. And Nordio M, Basciani S, Camajani E. Eur Rev Med Pharmacol Sci. 2019;23(12):5512-5521.
- Barrionuevo P, Nabhan M, Altayar O, et al. "Treatment Options for Hirsutism: A Systematic Review and Network Meta-Analysis." Journal of Clinical Endocrinology & Metabolism. 2018;103(4):1258-1264. And Alpañés M, Álvarez-Blasco F, Fernández-Durán E, et al. European Journal of Endocrinology. 2017;177(5):399-408.
- Elkind-Hirsch KE, Chappell N, Shaler D, Storment J, Bellanger D. "Liraglutide 3 mg on Weight, Body Composition, and Hormonal and Metabolic Parameters in Women With Obesity and Polycystic Ovary Syndrome." Fertility and Sterility. 2022;118(2):371-381. And Kar E, Yeh J, Efe MA, et al. Eur J Obstet Gynecol Reprod Biol. 2026.
Frequently Asked Questions
Common Questions
Deep-Dive Questions
Ready when you are
The chat is our AI assistant, answering from our published guides. To talk it through with Dr. Ash himself, start with the intake.





